Literature DB >> 9751409

Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human urothelial carcinomas.

Y Kitagawa1, K Kunimi, H Ito, H Sato, T Uchibayashi, Y Okada, M Seiki, M Namiki.   

Abstract

PURPOSE: Three different membrane-type matrix metalloproteinases (MT1, 2, 3-MMP) which can activate proMMP-2 (progelatinase A) are thought to have an important role in various human carcinoma invasions and metastases. We examined the mRNA expression of MT-MMPs and the tissue immunolocalization of MT1-MMP in human urothelial carcinomas.
MATERIALS AND METHODS: mRNA was extracted from 27 clinical urothelial carcinomas and 10 normal urothelial mucosa tissues remote from the tumor. RT-PCR using specific primers was performed, and PCR products were hybridized to 32P-labeled internal probes and analyzed by a bioimage analyzer. Immunolocalization was studied using a monoclonal antibody against MT1-MMP (114-6G6).
RESULTS: MT1-MMP and MT2-MMP mRNA expressions in urothelial carcinomas were significantly higher than those in the normal mucosa. In contrast, MT3-MMP mRNA was little expressed in both tissues, and the amount of MT3-MMP mRNA appeared to be much lower than MT1-MMP and MT2-MMP in the tissue samples. In terms of the tumor multiplicity, MT1-MMP and MT2-MMP mRNA expressions in the group of multiple tumors were significantly higher than those in the solitary tumor group. The carcinoma cells were immunostained for MT1-MMP predominantly in invasive and superficial carcinoma cells. The immunoreactivity was more intense in the invasive type than in the superficial type.
CONCLUSIONS: It is suggested that MT1-MMP and MT2-MMP play an important role in the development of human urothelial carcinomas and reflect some aspects of the pathogenesis of multifocal occurrence. In spite of the possible contribution to the invasive and metastatic phenotype, MT1-MMP mRNA and its product are thought to be expressed already in the clinical superficial stage in some cases of this tumor type.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751409

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Angiogenesis inhibitors.

Authors:  T R Tennant; C W Rinker-Schaeffer; W M Stadler
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

2.  Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors.

Authors:  M Nakada; H Nakamura; E Ikeda; N Fujimoto; J Yamashita; H Sato; M Seiki; Y Okada
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

3.  Profiling of matrix metalloproteinases and tissue inhibitors of metalloproteinases proteins in bladder urothelial carcinoma.

Authors:  Cheng-Keng Chuang; See-Tong Pang; Tai-Jung Chuang; Shuen-Kuei Liao
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

4.  Epigenetic modification suppresses proliferation, migration and invasion of urothelial cancer cell lines.

Authors:  Phillipp Brockmeyer; Bernhard Hemmerlein
Journal:  Oncol Lett       Date:  2016-07-18       Impact factor: 2.967

5.  Matrix Metalloproteinases and Bladder Cancer: What is New?

Authors:  O Rodriguez Faba; J Palou-Redorta; J M Fernández-Gómez; F Algaba; N Eiró; H Villavicencio; F J Vizoso
Journal:  ISRN Urol       Date:  2012-07-17

6.  Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.

Authors:  J E Nutt; H P Lazarowicz; J K Mellon; J Lunec
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.